A second-generation antibody-drug conjugate to treat HER2-positive breast cancer
- PMID: 36495878
- DOI: 10.1016/S0140-6736(22)02534-X
A second-generation antibody-drug conjugate to treat HER2-positive breast cancer
Conflict of interest statement
SD reports grants and non-financial support from Pfizer and AstraZeneca; and grants from Novartis, Roche Genentech, Lilly, Orion, Amgen, Sanofi, Genomic Health, Servier, MSD, BMS, Pierre Fabre, Exact Sciences, Besins, European Commission, French Government, Fondation ARC, Taiho, and Elsan, all of them in relation to clinical or translational research in the breast cancer early detection, prognostication, or treatment fields, all of them to their institution. ER reports no competing interests.
Comment on
-
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Lancet. 2023. PMID: 36495879 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous